26 patents
Utility
Combination Therapies for Treating Urothelial Carcinoma
11 Jan 24
Provided are methods of treating cancer (e.g., a urothelial cancer) that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPα-D1 domain variant and an Fc domain variant in combination with an antibody-drug conjugate (e.g., enfortumab vedotin).
Jaume PONS, Sophia RANDOLPH, Marija VRLJIC, Athanasios TSIATIS, Haiying LIU, Min Li, Amy Shaw-Ru CHEN
Filed: 31 May 23
Utility
Sirp-alpha Variant Constructs and Uses Thereof
26 Oct 23
The invention relates to compositions and methods of constructs comprising a SIRP-α polypeptide, including SIRP-a variants.
Laura DEMING, Corey GOODMAN, Jaume PONS, Bang Janet SIM, Marija VRLJIC
Filed: 14 Sep 22
Utility
Combination Therapies for Treating Cancer
13 Jul 23
Provided are methods of treating cancer that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPα D1 domain variant and an Fc domain variant in combination with at least one chemotherapy agent and/or at least one therapeutic antibody.
Hong WAN, Bang Janet SIM, Sophia RANDOLPH, Jaume PONS, Tracy Chia-Chien KUO
Filed: 13 Jan 23
Utility
Constructs having a SIRP-α domain or variant thereof
2 May 23
The present disclosure features signal-regulatory protein α (SIRP-α) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof.
Jaume Pons, Laura Deming, Corey Goodman, Bang Janet Sim, Steven Elliot Kauder, Hong Wan, Tracy Chia-Chien Kuo
Filed: 7 Jan 20
Utility
Methods of treating cancer
28 Mar 23
Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric/gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody).
Jaume Pons, Hong Wan, Sophia Randolph
Filed: 28 May 20
Utility
Antibodies Against Signal-regulatory Protein Alpha and Methods of Use
19 Jan 23
Provided herein, inter alia, are isolated antibodies that bind an extracellular domain of a human SIRP-α v1 polypeptide (e.g., the D1 domain), an extracellular domain of a human SIRP-α v2 polypeptide, or both.
Jaume PONS, Bang Janet SIM, Hong WAN, Tracy Chia-Chien KUO, Steven Elliot KAUDER, William Don HARRIMAN, Shelley IZQUIERDO
Filed: 2 Jun 21
Utility
Combination Therapies Comprising a Hypomethylation Agent for Treating Cancer
22 Dec 22
Provided are methods of treating cancer (e.g., a hematological cancer such as myelodysplastic syndrome) that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPα D1 domain variant and an Fc domain variant in combination with a hypomethylating agent (e.g., azacitidine).
Jaume PONS, Hong WAN, Sophia RANDOLPH
Filed: 28 May 21
Utility
Combination Therapies for Treating Cancer
17 Nov 22
Provided are methods of treating cancer that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPα D1 domain variant and an Fc domain variant in combination with at least one chemotherapy agent and/or at least one therapeutic antibody.
HONG WAN, Bang Janet SIM, Sophia RANDOLPH, Jaume PONS, Tracy Chia-Chien KUO
Filed: 12 May 22
Utility
Antibodies Against Signal-regulatory Protein Alpha and Methods of Use
13 Oct 22
Provided herein, inter alia, are isolated, humanized antibodies that bind an extracellular domain of a human SIRP-α polypeptide.
Jaume PONS, Bang Janet SIM, Hong WAN, Tracy Chia-Chien KUO
Filed: 22 Feb 22
Utility
Methods of Treating Cancer
4 Aug 22
Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric/gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody).
Jaume PONS, Hong WAN, Sophia RANDOLPH
Filed: 12 Apr 22
Utility
Antibodies against signal-regulatory protein alpha and methods of use
2 Aug 22
Provided herein, inter alia, are isolated antibodies that bind an extracellular domain of a human SIRP-α v1 polypeptide (e.g., the D1 domain), an extracellular domain of a human SIRP-α v2 polypeptide, or both.
Jaume Pons, Bang Janet Sim, Hong Wan, Tracy Chia-Chien Kuo, Steven Elliot Kauder, William Don Harriman, Shelley Izquierdo
Filed: 20 Sep 17
Utility
Multimers for Reducing the Interference of Drugs That Bind CD47 In Serological Assays
23 Jun 22
Provided are methods of reducing and/or preventing interference by a drug comprising (i) an antibody Fc region and (ii) a moiety that binds to human CD47 in serological assays.
Jaume PONS, Bang Janet SIM, Amy Shaw-Ru CHEN, Emma Ruth SANGALANG
Filed: 6 Dec 21
Utility
Antibodies against signal-regulatory protein α and methods of use
5 Apr 22
Provided herein, inter alia, are isolated, humanized antibodies that bind an extracellular domain of a human SIRP-α polypeptide.
Jaume Pons, Bang Janet Sim, Hong Wan, Tracy Chia-Chien Kuo
Filed: 20 Mar 19
Utility
Antibodies against signal-regulatory protein alpha and methods of use
8 Feb 22
Provided herein, inter alia, are isolated antibodies that bind an extracellular domain of a human SIRP-α v1 polypeptide (e.g., the D1 domain), an extracellular domain of a human SIRP-α v2 polypeptide, or both.
Jaume Pons, Bang Janet Sim, Hong Wan, Tracy Chia-Chien Kuo, Steven Elliot Kauder, William Don Harriman, Shelley Izquierdo
Filed: 2 Jun 21
Utility
Antibodies Against Signal-regulatory Protein Alpha and Methods of Use
6 Jan 22
Provided herein, inter alia, are isolated antibodies that bind an extracellular domain of a human SIRP-α v1 polypeptide (e.g., the D1 domain), an extracellular domain of a human SIRP-α v2 polypeptide, or both.
Jaume PONS, Bang Janet SIM, Hong WAN, Tracy Chia-Chien KUO, Steven Elliot KAUDER, William Don HARRIMAN, Shelley IZQUIERDO
Filed: 2 Jun 21
Utility
Constructs having a SIRP-alpha domain or variant thereof
28 Dec 21
The present disclosure features signal-regulatory protein α (SIRP-α) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof.
Jaume Pons, Bang Janet Sim, Steven Elliot Kauder, Hong Wan, Tracy Chia-Chien Kuo
Filed: 20 Mar 20
Utility
Sirp-alpha Variant Constructs and Uses Thereof
16 Dec 21
The invention relates to compositions and methods of constructs comprising a SIRP-α polypeptide, including SIRP-α variants.
Laura DEMING, Corey GOODMAN, Jaume PONS, Bang Janet SIM, Marija VRLJIC
Filed: 1 Feb 21
Utility
Antibodies Against Signal-regulatory Protein Alpha and Methods of Use
25 Nov 21
Provided herein, inter alia, are isolated antibodies that bind an extracellular domain of a human SIRP-α v1 polypeptide (e.g., the D1 domain), an extracellular domain of a human SIRP-α v2 polypeptide or both.
Jaume PONS, Bang Janet SIM, Hong WAN, Tracy Chia-Chien KUO, Steven Elliot KAUDER, William Don HARRIMAN, Shelley IZQUIERDO
Filed: 2 Jun 21
Utility
Decoy Polypeptides
11 Nov 21
Provided are decoy polypeptides comprising: (a) a SIRPγ variant, a SIRPβ1 variant, or a SIRPβ2 variant, and (b) a human Fc variant comprising at least one amino acid substitution that reduces effector function compared to a wild type human Fc.
Bang Janet SIM, Jaume PONS
Filed: 29 Aug 19
Utility
Combination Therapies for Treating Cancer
27 May 21
Provided are methods of treating cancer that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPα D1 domain variant and an Fc domain variant in combination with at least one chemotherapy agent and/or at least one therapeutic antibody.
Hong WAN, Bang Janet SIM, Sophia RANDOLPH, Jaume PONS, Tracy Chia-Chien KUO
Filed: 25 Nov 20